Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
Penicillin Prophylaxis in Sickle Cell Disease (PROPS)
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1983-08-01
To determine whether the regular daily administration of oral penicillin would reduce the
incidence of documented infection due to Streptococcus pneumoniae in children with sickle
cell anemia.
A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals
Completed
Hoffmann-La Roche
N/A
1969-12-31
To provide information on the response of HIV infected, neurosyphilis patients to the
currently recommended treatment for neurosyphilis; to determine whether possible
co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to
explore the usefulness of an alternative treatment which, if effective, would permit
outpatient treatment for neurosyphilis that until now required prolonged hospitalization.
Studies suggest that syphilis treatment failures may be more common in HIV infected patients
than in patients without HIV infection and that treatment failures occur due to and/or are
displayed as central nervous system (CNS) involvement. Very little is known about the best
treatment course for neurosyphilis in patients who are also infected with HIV.
A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
1969-12-31
To provide information on the response of HIV infected, neurosyphilis patients to the
currently recommended treatment for neurosyphilis; to determine whether possible
co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to
explore the usefulness of an alternative treatment which, if effective, would permit
outpatient treatment for neurosyphilis that until now required prolonged hospitalization.
Studies suggest that syphilis treatment failures may be more common in HIV infected patients
than in patients without HIV infection and that treatment failures occur due to and/or are
displayed as central nervous system (CNS) involvement. Very little is known about the best
treatment course for neurosyphilis in patients who are also infected with HIV.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
